A personalized mRNA vaccine layered on top of Merck's Keytruda extended recurrence-free and metastasis-free survival in 1,137 patients whose melanoma had been surgically cleared. It's the first positive Phase 3 readout for both mRNA and individualized neoantigen cancer therapy. Moderna spiked as much as ~70% premarket, with prior five-year data showing a 49% lower risk of recurrence or death. Full data comes at an oncology conference; FDA filing is next.
For the first time in a decade, hyperscalers are funding AI infrastructure with borrowed money at scale: ~$35B of debt a year from 2020-24 became $93B in 2025 and roughly $132B already this year, including one of the largest corporate bond sales on record. Vanguard reads the shift as a maturing investment cycle, not distress, but S&P has already cut Oracle to BBB- on negative cash flow. Bond investors, not just equity holders, now carry the AI boom.
Samsung Electronics says 2026 shareholder returns will hit 90-110 trillion won (up to $79.5B), the largest package ever by a Korean company, and a direct reply to SK Hynix's 40 trillion won buyback days earlier. Roughly 30 trillion won lands as Q3 cash dividends. The stock is up ~135% year-to-date on AI memory demand; final details land at a late-January board meeting.
SK Hynix shares jumped more than 12% in Seoul after the memory maker said it is accelerating a 40 trillion won ($28.7 billion) buyback and cancellation program. It also committed to handing out over 50% of cumulative free cash flow from 2025 to 2027 to shareholders. Analysts call the repurchase a floor for the share price and a vote of confidence in the AI buildout SK Hynix is funding with billions in new memory plants.